About Herbal Medicines

References

  1. Kessler RC et al Long–term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001; 135: 262–268.(PubMed)
  2. Barnes J. Herbal medicine. Pharm J 1998; 260: 344–348.
  3. House of Lords Select Committee on Science and Technology Session 1999–2000, 6th Report. Complementary and Alternative Medicine. 21st November 2000.
  4. Ernst E, White AR. The BBC survey of complementary medicine use in the UK. Complement Ther Med 2000; 8: 32–36.(PubMed)
  5. Thomas KJ et al. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 2001; 9: 2–11.(PubMed)
  6. Brevoort P. The US botanical market – an overview. Herbalgram 1996; 36: 49–57.
  7. Brevoort P. The booming US botanical market. A new overview. Herbalgram 1998; 44: 33–46.
  8. Blumenthal M. Herbs and phytomedicines in the European Community. In: Blumenthal M, ed. The Complete German Commission E Monographs. Therapeutic Guide to Herbal Medicines. Austin, Texas: American Botanical Council, 1998.
  9. Institute of Medical Statistics (IMS) Self-Medication International. Herbals in Europe. London: IMS Self-Medication International, 1998.
  10. EMEA Herbal Medicinal Products Working Party. Position paper on the risks associated with the use of herbal products containing Aristolochia species. EMEA website: www.eudra.org/emea.html. October 2001.
  11. Barnes J et al. St. John’s Wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53: 583–600.(PubMed)
  12. Evans WC. Trease and Evans’ Pharmacognosy, 14th edn. London: WB Saunders, 1998.
  13. Council Directive 65/65/EEC. Official Journal of the European Communities 1965; 22: 369.
  14. Britt R. The New EC Systems in the UK, Regulatory Affairs J 1995; 6: 380–384.
  15. AESGP (Association of the European Self–medication Industry). Herbal Medicinal Products in the European Union, 15 March 1999. .
  16. Steinhoff B. The contribution of the European Scientific Cooperative on Phytotherapy and World Health Organisation monographs. Drug Inform J 1999; 33: 17–22.
  17. Monographs on the Medicinal Uses of Plant Drugs, Fascicules 1 and 2 (1996), Fascicules 3, 4 and 5 (1997), Fascicule 6 (1999). Exeter: European Scientific Cooperative on Phytotherapy (ESCOP)
  18. European Commission, CPMP Guidelines on Information on Medicinal Products: Core SPCs for Frangulae Cortez, Sennae Fructus Angustifoliae, Sennae Fructus Acutifoliae, Sennae Folium, February 1994.
  19. European Medicines Evaluation Agency. Herbal Medicinal Products Working Party Draft Core Summary of Product Characteristics for Valerian and Ispaghula. . October, 2001.
  20. Official Journal of the European Communities No. C 305 of 16 October 1987.
  21. Draft of Provisions of a Directive on Traditional Herbal Medicinal Products. . February 2002.
  22. Medicines Act Leaflet (MAL) 8. A Guide to the Status under the Medicines Act of Borderline Products for Human Use. London: Medicines Control Agency.
  23. Statutory Instrument (SI) 1994:3144, The Medicines for Human Use (Marketing Authorisations Etc) Regulations.
  24. The Medicines Act, l968. London: HM Stationery Office.
  25. Appelbe GE, Wingfield J. Dale and Appelbe’s Pharmacy Law and Ethics, 6th edn. London: The Pharmaceutical Press, 1997.
  26. CPMP/QWP 2819/00 (EMEA/CVMP 814/00) Note for Guidance. Quality of Herbal Medicinal Products. EMEA website: www.eudra.org/emea.html. October 2001.
  27. CPMP/QWP 2820/00 (EMEA/CVMP 814/00) Note for Guidance. Specifications: test procedures and acceptance criteria for herbal drugs, herbal drug preparations and herbal medicinal products. EMEA website: www.eudra.org/emea.html. October 2001.
  28. CPMP/CVMP Note for Guidance on Manufacture of Herbal Medicinal. Products. The Rules Governing Medicinal Products in the European Union 1992, vol. IV: 127–129.
  29. Statutory Instrument (SI) 1971: 1450, The Medicines (Exemptions from Licences) (Special and Transitional Cases) Order.
  30. Anon. Herbal licensing position confirmed. Pharm J 1994; 253: 746.
  31. De Smet PAGM. Should herbal medicine–like products be licensed as medicines? BMJ 1995; 310: 1023–1024.(PubMed)
  32. Vautier G, Spliller RC. Safety of complementary medicines should be monitored. BMJ 1995; 311: 633.(PubMed)
  33. Holder S. Regulatory aspects of herbal medicines: a global view. The Regulatory Review 2001; 4: 13–17.
  34. Statutory Instrument (SI) 1984: 769, The Medicines (Products Other than Veterinary Drugs) (General Sales List) Order, 1984, as amended by SI 1985:1540, SI 1987: 910, SI 1989: 969 and SI 1990: 1129.
  35. Statutory Instrument (SI) 1983: 1212, The Medicines (Products Other than Veterinary Drugs) (Prescription Only) Order 1983, as amended.
  36. Statutory Instrument (SI) 1977: 2130, (The Medicines Retail Sale or Supply of Herbal Remedies) Order, 1977.
  37. Statutory Instrument (SI) 2001:1841, The Medicines (Aristolochia and Mu Tong etc) (Prohibition) Order, 2001.
  38. Medicines Control Agency. Review of herbal ingredients for use in unlicensed herbal medicinal products. September 2001. www.mca.gov.uk.
  39. Medicines Act Leaflet (MAL 2). Guidelines on Safety and Efficacy Requirements for Herbal Medicinal Products. Guidance Notes on Applications for Product Licences; 1989, 53–54.
  40. Anon. Regulatory Situation of Herbal Medicines – a Worldwide Review. Geneva: WHO, 1998: 1–45.
  41. Boon H, Smith M. The Botanical Pharmacy – the Pharmacology of 47 Common Herbs, 2nd edn. Kingston, Ontario: Quarry Health and the College of Naturopathic Medicine, 2000.
  42. Anon. Further developments to the NHPD working draft of the proposed regulatory framework for NHPs. Health Canada. www.hc–sc.gc.ca/hpb/onhp/nph_reg_frame_nov21_upd_e.html. October, 2001.
  43. Foster S, Tyler VE. Tyler’s Honest Herbal, 4th edn. New York: Haworth Press, 1999.
  44. De Smet PAGM. Toxicological outlook on quality assurance of herbal remedies. In: Adverse Effects of Herbal Drugs, vol 1. Berlin: Springer Verlag, 1992.
  45. De Smet PAGM. Overview of Herbal Quality Control. Drug Inform J 1999; 33: 717–724.
  46. Bauer R. Quality Criteria and Standardization of Phytopharmaceuticals: Can acceptable drug standards be achieved? Drug Inform J 1998, 32: 101–110.
  47. Busse W. The significance of quality for efficacy and safety of herbal medicinal products. Drug Inform J 2000, 34: 15–23.
  48. Corbin Winslow L. Herbs as Medicines. Arch Intern Med 1998: 158: 2192–2199.(PubMed)
  49. Medicines Control Agency. Traditional Medicines: Public Health and Compliance with Medicines Law. www.mca.gov.uk. November 2001.
  50. Vanherweghem, J-L, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 135–139.
  51. Cosyns, J-P et al. Chinese herbs nephropathy: A clue to Balkan endemic nephropathy. Kidney Int 1994; 45: 1680–1688.(PubMed)
  52. Van Ypersele C, Vanherweghem J-L. The tragic paradigm of Chinese herb nephropathy. Nephrol Dial Transplant 1995; 10: 157–160(PubMed)
  53. Cosyns J-P et al. Urothelial lesions in Chinese–herb nephropathy. Am J Kidney Dis 1999; 33: 1011–1017.(PubMed)
  54. Lord G et al. Nephropathy caused by Chinese herbs in the UK. Lancet 1999; 354: 481–482.(PubMed)
  55. FDA Press Release. Vital Nutrients Recalls Joint Ease & Verified Quality Brand Joint Comfort Complex because of adverse health risk associated with aristolochic acid. www.fda.gov-USA. June 2001.
  56. Charvill A. Investigation of formulated Traditional Chinese Medicines (TCM) and raw herbs for the presence of Aristolochia species. British Pharmaceutical Conference Science Proceedings 2001. London: Pharmaceutical Press, 2001: 295.
  57. Slifman NR. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med 1998; 339: 806–811.(PubMed)
  58. But PPH et al. Adulterants of herbal products can cause poisoning. BMJ 1996; 313: 117.
  59. Tai Y-T et al. Cardiotoxicity after accidental herb–induced aconite poisoning. Lancet 1992; 340: 1254–1256.(PubMed)
  60. Pharmacopoeia of the People’s Republic of China (English edition). Chemical Industry Press, 2000.
  61. Ko R. Adulterants in Asian patent medicines. N Engl J Med 1998; 339: 847.(PubMed)
  62. Au AM et al. Screening methods for drugs and heavy metals in Chinese patent medicines. Bull Environ Contam Toxicol 2000; 65: 112–119.(PubMed)
  63. Koh H-L, Woo S-O. Chinese Proprietary Medicine in Singapore: Regulatory control of toxic heavy metals and undeclared drugs. Drug Safety 2000; 23: 351–362.(PubMed)
  64. Huang WF et al. Adulteration by synthetic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997; 37: 344–350.(PubMed)
  65. Singapore Ministry of Health Press Statement. Chinese Proprietary Medicine Found Adulterated with Sildenafil. 3 March 2001.
  66. FDA Press Release. Anso Comfort Capsules Recalled by Distributor. 13 February 2001. www.fda.gov-USA
  67. Lau KK et al. Phenytoin poisoning after using Chinese proprietary medicines. Hum Exp Toxicol 2000; 19: 385–386.(PubMed)
  68. FDA Press Release. State Health Director Warns Consumers about Prescription Drugs in Herbal Products. 15 February 2000. www.fda.gov-USA.
  69. Medicines Control Agency. Hypoglycaemia following the use of Chinese herbal medicine Xiaoke Wan. Curr Probl Pharmacovigilance 2001; 27: 8.
  70. Wu M-S. Multiple tubular dysfunction induced by mixed Chinese herbal medicines containing cadmium. Nephrol Dialysis Transplant 1996; 11: 867–870.
  71. Schaumburg HH et al. Alopecia and sensory polyneuropathy from thallium in a Chinese herbal medication. JAMA. 1992; 268: 3430–3431.(PubMed)
  72. Kew J et al. Arsenic and mercury intoxication due to Indian ethnic remedies. BMJ 1993; 306: 506–507.(PubMed)
  73. Sheerin NS et al. Simultaneous exposure to lead, arsenic and mercury from Indian ethnic medicines. Br J Clin Pharmacol 1994; 48: 332–333.
  74. Cuncha J et al. Arsenic and acute lethal intoxication. Hong Kong Pharm J 1998; 7: 50–53.
  75. EMEA Herbal Medicinal Products Working Party. Points to Consider on Good Agricultural and Collection Practice for Starting Materials of Herbal Origin. EMEA website: www.eudra.org/emea.html. October 2001.
  76. World Health Organization. Quality Control of Medicinal Plant Materials. Geneva: World Health Organization, 1998.
  77. European Pharmacopoeia, 4th edn. 2002. Strasbourg: Council of Europe, 2002.
  78. Phillipson JD. Quality assurance of medicinal plants. In: Franz C et al. First World Congress on medicinal and aromatic plants for human welfare, WOCMAP, quality, phytochemistry, industrial aspects, economic aspects. Acta Horticult 1993; 333: 117–122.
  79. Houghton P. Establishing identification criteria for botanicals. Drug Inform J 1998; 32: 461–469.
  80. De Smet PAGM. Health risks of herbal remedies. Drug Safety 1995; 13: 81–93.(PubMed)
  81. De Smet PAGM. Adverse effects of herbal remedies. Adverse Drug React Bull 1997; 183: 695–698.
  82. Shaw D et al. Traditional remedies and food supplements. A 5–year toxicological study (1991–1995). Drug Safety 1997; 17: 342–356.(PubMed)
  83. Tisserand R, Balacs T. Essential Oil Safety. Edinburgh: Churchill Livingstone, 1995.
  84. De Smet PAGM. Aristolochia species. In: Adverse Effects of Herbal Drugs, vol 1. Berlin: Springer Verlag, 1992.
  85. D’Arcy PF. Adverse reactions and interactions with herbal medicines. Part 1. Adverse reactions. Adverse Drug React Toxicol Rev 1991; 10: 189–208.(PubMed)
  86. Mattocks AR. Chemistry and Toxicology of Pyrrolizidine Alkaloids. New York: Academic Press, 1986.
  87. Anderson LA, Phillipson JD. Mistletoe – the magic herb. Pharm J 1982; 229: 437–439.
  88. Tyler VE. The Honest Herbal, 3rd edn. New York: Howarth Press, 1993.
  89. Chandler RF et al. Controversial laetrile. Pharm J 1984; 232: 330–332.
  90. Statutory Instrument (SI) 1984:87. The Medicines (Cyanogenetic Substances) Order 1984.
  91. Ljunggren B. Severe phototoxic burn following celery ingestion. Arch Dermatol 1990; 126: 1334–1336.(PubMed)
  92. Boffa MJ et al. Celery soup causing severe phototoxicity during PUVA therapy. Br J Dermatol 1996; 135: 330–345.(PubMed)
  93. Medicines Control Agency. Psoralea corylifolia fruit in Traditional Chinese Medicines causing severe skin reaction. Curr Probl Pharmacovigilance 2001; 27: 12.
  94. Baldwin CA et al. What pharmacists should know about ginseng. Pharm J 1986; 237: 583–586.
  95. Baldwin CA et al. What pharmacists should know about feverfew. Pharm J 1987; 239: 237–238.
  96. Roulet M et al. Hepatic veno–occlusive disease in newborn infant of a woman drinking herbal tea. J Pediatr 1988; 112: 433–436.(PubMed)
  97. Allen JR et al. Are herbal teas safe for infants and children. Aust Family Physician 1989; 18: 1017–1019.
  98. Ernst E. Herbal Medications for common ailments in the elderly. Drugs Ageing 1999; 15: 423–428.
  99. Mashour NH. Herbal medicine for the treatment of cardiovascular disease. Arch Intern Med 1998; 158: 2225–2234.(PubMed)
  100. Ang–lee MK et al. Herbal medicines and peri operative care. JAMA 2001; 286: 208–216.(PubMed)
  101. American Society of Anesthesiologists (ASA). www.asahq.org/PublicEducation/herbal.html. September 2001.
  102. Ernst E. Possible interactions between synthetic and herbal medicinal products. Perfusion 2000; 13: 4–15.
  103. Fugh-Berman A. Herb–drug interactions. Lancet 2000; 355: 134–138.(PubMed)
  104. Miller L. Selected clinical considerations focusing on known and potential drug–herb interactions. Arch Intern Med 1998; 158: 2200–2211.(PubMed)
  105. Brown R. Potential interactions of herbal medicines with antipsychotics, antidepressants and hypnotics. Eur J Herb Med 1997; 3: 25–28.
  106. Boyle F. Herbal medicines can interfere with breast cancer treatment. Med J Aust 1997; 167: 286.(PubMed)
  107. Cheng TO. Herbal interactions with cardiac drugs. Arch Intern Med 2000; 160: 870–871.(PubMed)
  108. Anon. Grapefruit and drug effects. Drugs Q 1999; 3: 25–28.
  109. Barnes J et al. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face–to–face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496–500.(PubMed)
  110. Farah MH et al. International reporting of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Safety 2000; 9: 105–112.
  111. Ernst E, Pittler MH. The efficacy of herbal drugs. In: Herbal Medicine: a Concise Overview for Professionals. London: Butterworth-Heinemann, 2000: 69–81.
  112. Ernst E. The clinical efficacy of herbal treatments: an overview of recent systematic reviews. Pharm J 1999; 262: 85–87.
  113. Ernst E. Herbal medicines: where is the evidence? BMJ 2000; 321: 395–396.(PubMed)
  114. The Cochrane Library.
  115. Williamson EM. Synergy – myth or reality? In: Herbal Medicine: a Concise Overview for Professionals. London: Butterworth-Heinemann, 2000: 43–58.
  116. Wurglics M et al. Comparison of German St John’s Wort Products according to hyperforin and total hypericin content. J Am Pharm Assoc 2001; 41: 560–566.
  117. Bergonzi MC et al. Variability in the content of the constituents of Hypericum perforatum L. and some commercial extracts. Drug Dev Indust Pharm 2001; 26: 491–497.
  118. Melchart D et al. Echinacea for the prevention and treatment of the common cold (Cochrane review). The Cochrane Library, Issue 1, 2002. Oxford: Update Software.